Ban on Direct-to-Consumer Advertising for Prescription Drugs and Medication-Containing Devices (1624)

2019 ◽  
pp. 513c-513c
Keyword(s):  
Prescription Drugs ◽  
Direct To Consumer ◽  
Direct To Consumer Advertising

scholarly journals Controversial advertising of medicines. A comparison between Poland and the United States

2018 ◽  
Vol 21 (5) ◽  
pp. 67-79
Author(s):  
Marta Makowska
Keyword(s):  
United States ◽  
Prescription Drugs ◽  
The United States ◽  
The European Union ◽  
Negative Consequences ◽  
Direct To Consumer ◽  
Law And Ethics ◽  
The Us ◽  
The Law ◽  
Direct To Consumer Advertising

For many years, the subject of aggressive marketing campaigns conducted by pharmaceutical companies has been raised in Poland. Drug ads are everywhere, on television, the radio, magazines and on the Internet. Therefore, it is extremely important is to ensure both their legal and ethical dimension. This article will present the differences between direct-to-consumer advertising of medicines in Poland and in the US. The dissimilarities result mainly from differences in legislation. In Poland, the law is much stricter than in the US. For example, in the United States companies are allowed to advertise prescription drugs directly to patients. In the whole of the European Union, and thus in Poland, it is strictly prohibited. The article will also present other regulations existing in Poland and in the United States and it will compare them. It will offer examples of violations of the law and ethics in the advertising of medicine in both countries. Lastly, it will briefly outline the negative consequences of unacceptable pharmaceutical marketing.

Integrating ethics with strategy: analyzing disease‐branding

2007 ◽  
Vol 12 (3) ◽  
pp. 267-279 ◽  
Author(s):  
Patricia J. Parsons
Keyword(s):  
Prescription Drugs ◽  
Planning Process ◽  
Ethical Analysis ◽  
Corporate Communication ◽  
Communication Strategy ◽  
Content Type ◽  
Direct To Consumer ◽  
Integrating Ethics ◽  
Litmus Test ◽  
Direct To Consumer Advertising

PurposeThe purpose of this paper is to analyze the ethics of a specific communication strategy to support the contention that ethics needs to be an integrated operational consideration in the corporate communication planning process rather than an afterthought.Design/methodology/approachUsing the marketing communication strategy referred to as disease branding as a case‐in‐point, the “Five Pillars of Ethics for Public Communication” provide a framework for analysis of the need for making ethics an operational consideration in planning.FindingsCommunication strategies attempted by organizations today are subject to public criticism. Disease branding, a prime example, is paradoxically a “non‐branded” approach to marketing pharmaceuticals directly to consumers. Pejoratively referred to as disease‐mongering, this promotion of diseases rather than drugs neatly side‐steps the increasing criticism and even legal obstacles that face or threaten to face direct‐to‐consumer advertising of branded, prescription drugs. It is an innovative, non‐traditional tactic that has been enormously successful in widening markets for specific drug preparations. Application of the “Five Pillars” for ethical analysis finds that this strategy fails to meet the acceptable ethical standard in four out of five.Research limitations/implicationsThis study is limited to the application of one approach to ethical evaluation, although it is one that encompasses a number of widely accepted standards for practice.Practical implicationsAn ethical analysis using the “Five Pillars” can be implemented by any corporate communication professional as a litmus test for determining the ethics of strategies under development during the operational planning process.Originality/valueThis paper fills a gap in the information available to corporate communication professionals about how to operationalize ethics.

Sign in / Sign up

Export Citation Format

Share Document